Abstract 179P
Background
Interpreting next-generation sequencing (NGS) results and directing treatment based on those results can be challenging. Molecular tumor boards (MTBs) can help by establishing collaborative frameworks to deliver patient care plans with the appropriate incorporation of genomic data.
Methods
This retrospective observational study evaluates the impact of MTB on the outcomes of adult patients diagnosed with advanced-stage cancer. Patients were grouped into those who received at least one treatment recommended by MTB or those who did not receive treatment recommended by MTB. Kaplan- Meier analysis was performed for overall survival (OS) and progression-free survival (PFS). Cox proportional hazard model was fit for PFS, OS, and time on treatment (ToT) with multivariate adjusting for age, stage, line of therapy, and primary site of diagnosis.
Results
Of 238 evaluable patients, 138 (58%) received at least one treatment recommended by MTB. Patient characteristics were well balanced between the cohorts except for a statistically significantly higher proportion of lung adenocarcinoma (33% v 14%, p=0.0009) & melanoma (9% v 2%, p=0.030) in the matched cohort and more glioblastoma in the unmatched cohort (8% v 1%, p=0.017) (Table). Median ToT was 4.3 months for patients on matched treatment versus 2.8 months for patients who received therapy of provider's choice (HR 0.58, 95% CI [0.41-0.83], p=0.0027). Median PFS was 9.7 months versus 4.3 months for MTB-matched treatment versus provider's choice of treatment (HR 0.64, 95% CI [0.42-0.97],p=0.035). Median OS was 18.5 months for patients on MTB-recommended therapy versus 9.1 months for patients who received therapy of provider's choice (HR 0.64, 95% CI [0.43-0.96],p=0.030).
Conclusions
MTB treatment recommendations improved survival outcomes for patients with cancer even after correcting for imbalances between the two cohorts. Our findings show that MTBs in community cancer centers are feasible and valuable in cancer care. Table: 179P
Histology
Matched | Unmatched | |||||||
No. | (%) | No. | (%) | |||||
138 | 100 | |||||||
Lung Adenocarcinoma | 45 | (33%) | 14 | (14%) | ||||
Colorectal Adenocarcinoma | 10 | (7%) | 14 | (14%) | ||||
Breast Carcinoma | 8 | (6%) | 12 | (12%) | ||||
Melanoma | 12 | (9%) | 2 | (2%) | ||||
Lung Squamous Cell Carcinoma | 7 | (5%) | 7 | (7%) | ||||
Prostatic Adenocarcinoma | 5 | (4%) | 6 | (6%) | ||||
Glioblastoma | 2 | (1%) | 8 | (8%) | ||||
Esophagogastric Adenocarcinoma | 5 | (4%) | 5 | (5%) | ||||
Pancreatic Adenocarcinoma | 2 | (1%) | 6 | (6%) | ||||
Cholangiocarcinoma | 6 | (4%) | 1 | (1%) | ||||
Non-cutaneous Squamous Cell Carcinoma | 6 | (4%) | 1 | (1%) | ||||
Lung Small Cell Carcinoma | 2 | (1%) | 4 | (4%) | ||||
Endometrial Carcinoma | 3 | (2%) | 1 | (1%) | ||||
Sarcoma | 1 | (1%) | 3 | (3%) | ||||
Urothelial Carcinoma | 1 | (1%) | 2 | (2%) | ||||
Appendiceal Adenocarcinoma | 2 | (1%) | 1 | (1%) | ||||
Other Histologies | 21 | (15%) | 13 | (13%) |
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Saint Luke's Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
144P - Artificial intelligence supported treatment decisions for precision oncology
Presenter: Damian Rieke
Session: Poster session 01
145P - Identification of biomarkers of survival across multiple cancer types using eXplainable artificial intelligence
Presenter: Francesca Angileri
Session: Poster session 01
147P - Non-small cell lung cancer: Artificial intelligence enables the identification of survival signatures complementary to an Immunologically active gene expression signature involving previous therapies
Presenter: Pierre Saintigny
Session: Poster session 01
149P - Assessing the effect of single dose trastuzumab and pertuzumab (HP) on biological changes and pathological complete response (pCR) in ERBB2+ Breast Cancer: Results from the neoadjuvant BionHER study
Presenter: Nadia Gomez Serra
Session: Poster session 01
150P - Validation of a genomic assay in early-stage HER2+ breast cancer (BC) treated with trastuzumab and pertuzumab (HP): A correlative analysis from PHERGain phase II trial
Presenter: Antonio Llombart Cussac
Session: Poster session 01
152P - Efficacy of olaparib in advanced cancers with germline or somatic tumor mutations in BRCA1, BRCA2, CHEK2 and ATM: A Belgian precision tumor-agnostic phase II study
Presenter: Sofie Joris
Session: Poster session 01
153P - Descriptive analysis of the location of point mutations in BRCA and the risk of breast or ovarian cancer diagnosis
Presenter: Pablo Torres-Mozas
Session: Poster session 01
154P - Highly sensitive serum volatolomic biomarkers for pancreatic cancer diagnosis and prognosis
Presenter: Alfredo Martínez
Session: Poster session 01